Breckenridge Pharmaceutical, the U.S. subsidiary of Towa International, announced the launch of Tofacitinib Tablets, the generic equivalent of Xeljanz® by Pfizer, in the disease-modifying antirheumatic drug category.
Tofacitinib Tablets are Janus kinase (JAK) inhibitors, a class of medicines that block the activity of JAK enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Tofacitinib Tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and moderately to severely active ulcerative colitis (UC), in all cases who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. TNF is a substance in the body that can cause inflammation and lead to immune-system diseases, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
In addition, Tofacitinib Tablets are indicated for the treatment of pediatric patients 2 years of age and older with PsA and active polyarticular course juvenile idiopathic arthritis, who have had an inadequate response or intolerance to one or more TNF blockers.
Tofacitinib Tablets are available in 5 mg and 10 mg strengths and provide a flexible dosing option to support individualized treatment approaches across approved indications.
Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, Inc., commented: "The launch of our generic version of Tofacitinib reflects Breckenridge's commitment to expanding access to essential therapies for patients living with chronic inflammatory conditions, including pediatric populations. By offering a high-quality, cost-effective generic option, we aim to support healthcare providers with a reliable supply while helping reduce financial barriers and improve continuity of care for both children and adults."
Tofacitinib Tablets are manufactured at the production facility within the international hub of Breckenridge Pharmaceutical, Towa International, located in Martorelles, Barcelona, Spain.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!